$CLOV

THORNTON JOSEPH CLAY sold $22K of CLOV

THORNTON JOSEPH CLAY (Interim CFO) sold 4,630 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.67 on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · THORNTON JOSEPH CLAY
Published Jul 16, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The newest fact is the reported open-market sale amount, price, and post-transaction holdings by an officer (Interim CFO) under a pre-arranged 10b5-1 plan.

02

Market read

This is a routine insider sale disclosure; it is more relevant for sentiment monitoring than for a direct trading catalyst.

03

What to watch

The filing does not disclose any new company performance, guidance, or risk event; traders should avoid over-weighting it versus fundamentals and upcoming disclosures.

Relevance 2/10Novelty 3/10Timing: filed 2026-07-16, transaction dated 2026-07-15

Background

The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp. (DE).

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover Health insider Thornton Joseph Clay sold 4,630 shares at $4.67 under a 10b5-1 plan, per a newly filed Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider trading with no disclosed operational or regulatory change.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Clover Health Investments, Corp. (DE)

    Subject of the Form 4 insider transaction disclosure.

  • Thornton Joseph Clay

    Interim CFO who sold 4,630 shares at $4.67 under a 10b5-1 plan.

Related articles

$CLOVMedAI 8/10

Clover Health Investments Q2 Earnings Call Highlights

Clover Health Investments (CLOV) reported Q2 adjusted EBITDA of $41 million and GAAP net income of $28 million. For the first half of 2026, it posted $81 million adjusted EBITDA and $55 million GAAP net income, with $443 million cash and investments and no debt. The company raised 2026 guidance to $2.92B-$3.0B revenue and $70M-$85M adjusted EBITDA, and discussed cohort maturation and 4.5-star ratings for 2027.

$METMed

Financial results round-up: MetLife, Prudential, Corebridge, Palomar, Heritage, TWFG, Root and more

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.

$CLOVHighAI 9/10

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV): Results of Operations and Financial Condition

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26exx991xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Clover Health Reports Second Quarter 2026 Results Business Highlights: • Delivered strong second quarter 2026 GAAP Net Income alongside continued market-leading Medicare Advantage membership growth • Improved

$CLOVMed

What's Fueling Clover Health's Recent Stock Surge

Clover Health (CLOV) shares rose about 7% to $2.39 after UnitedHealth Group (UNH) reported strong Q1 2026 results and raised its full-year adjusted net earnings outlook to over $18.25 per share, lifting sentiment for health insurers. Clover also cited 53% YoY Medicare Advantage membership growth and reiterated 2026 GAAP net income profitability guidance. Analysts maintain a Hold rating and a $2.90 average target.